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Abstract
The role and optimal duration of neoadiuvant chemotherapy (NACT) in adevanced ovarian cancer is debated.
The use of PET/CT after 3 cycles of NACT as a determinant of pathological response, PFS and OS was studied
in 50 patients treated with a total of 6 cycles. Complete metabolic response by PET/CT allows to identify
patients who benefit from extending the duration of NACT and with a better outcome.
Background and Aim: Early complete metabolic response (e-CMR) by fluorine-18 fluorodeoxyglucose positron emission
tomography (FDG-PET) during neoadjuvant chemotherapy (NACT) in advanced ovarian cancer (AOC) could have predictive and
prognostic value. The present explorative study prospectively investigated changes of dual-time FDG-PET, at baseline and after
3 cycles of NACT in patients whowere not candidates for upfront debulking surgery by comparing with standard serum cancer
antigen 125 (CA-125) monitoring. Patients and Methods: Fifty consecutive patients with AOC were treated with 6 cycles of
carboplatin/paclitaxel before surgery. FDG-PET and serum CA-125 were evaluated at baseline and after 3 cycles. e-CMR and
early complete biochemical response (e-CBR) were defined as the normalization of the maximum standardized uptake values
and serumCA-125 levels, respectively.Results: e-CMR and e-CBRwere observed in 34% and 38%of patients, respectively.
At the end of NACT, an optimal pathologic response (pR) and optimal surgery with no residual tumor (R0) were achieved in 23
(46%) and 26 (52%) patients, respectively. E-CMRand e-CBRpositive predictive valuewas 88%and 84% for pR and 88%and
89% for R0, respectively. After amedian follow-up of 42months, 41 (82%) patients had progressed and 32 (64%) died.Median
progression-free survival and overall survival were 13.8 and 28.1 months, respectively. At multivariate analysis, e-CMR, but not
e-CBR, showed an independent prognostic value with regard to both progression-free survival and overall survival.
Conclusions: e-CMRmay predict pR and R0 surgery obtained at the end of NACT and identify patients a favorable long-term
outcome.
Clinical Ovarian & Other Gynecologic Cancer, Vol. 5, No. 1, 2-9 © 2012 Elsevier Inc. All rights reserved.
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Two-thirds of patients with ovarian cancer have disease at presenta-
tion.1 Although an upfront surgical approach is the first treatment op-
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sterm life expectancy.2-5 Neoadjuvant chemotherapy (NACT), defined
s the administration of chemotherapy before any surgery, is making
eadway as an alternative approach when upfront optimal cytoreduction
annot be achieved.6 The concept of NACT followed by interval deb-
lking surgery (IDS) after 3 or more cycles has emerged and is now being
idely used.7-18 However, a meta-analysis including a large series of
heterogeneous phase I-II studies reported that NACT was associated
with inferior overall survival compared to initial cyto-reductive surgery
and that survival was negatively affected with increasing number of che-
motherapy cycles prior to interval surgery.19
Recently, the 2 strategies were prospectively compared by the Eu-
ropean Organization for Research and Treatment of Cancer-Gynae-
cological Cancer Group20 in a large phase III randomized trial. The
study showed that NACT followed by IDS was not inferior to pri-
mary debulking surgery followed by chemotherapy as a treatment
option for patients with bulky stage IIIC or IV ovarian cancer. For
patients who are candidates for NACT followed by IDS, the optimal
chemotherapy duration has not yet been defined. At the moment, 2
duration models can be suggested: the first entails 2-3 cycles followed
by IDS and subsequently 3-4 additional cycles of chemotherapy,
and, the second entails 5-6 NACT cycles followed by a definitive
surgical intervention.21
The availability of a dynamic test that predicts optimal sensitivity to
cytotoxic treatment could allow us to tailor the NACT duration in pa-
tients with advanced ovarian cancer (AOC) who were unsuited to up-
front aggressive surgery. During NACT, the test changes should identify
early those patients who have a high chemosensitive tumor and who
could be selected for postponement of debulking surgery with a high
likelihood of obtaining an optimal pathologic response (pR) and opti-
mal surgery. CA-125 is currently the most widely used tumor marker for
AOC, and serial level determinations during chemotherapy are useful
for assessing treatment response.22 However, recent guidelines by an
expert international panel have indicated that the prognostic informa-
tion supplied by CA-125 up to the start of the third course of chemo-
therapy is not accurate enough to manage individual patients.23
Several researchers have shown that fluorine-18 fluorodeoxyglu-
cose positron emission tomography (FDG-PET) may play a role in
predicting patient response and outcome to chemotherapy for many
solid tumors24-28 and lymphomas.29 However, only a few small stud-
es so far have investigated the usefulness of FDG-PET in predicting
esponse to NACT and patient outcome in gynecologic cancer.30-33
Recently, we reported that patients with AOC who present normal-
ization of maximum standardized uptake value (SUVmax) by FDG-
PET after 3 cycles of NACT have a high likelihood of benefiting
from 3 additional cycles to obtain a pR and to receive optimal sur-
gery.34 The present explorative study, which is part of a larger study
roject named the “Arianna 2 project” has prospectively investigated
he predictive and prognostic value of dual-time FDG-PET, at base-
ine and after 3 cycles of NACT, in patients who were not candidates
or upfront debulking surgery by comparing that value with standard
erum CA-125 monitoring.
Patients and Methods
Patients
Women with newly diagnosed histologically proven advanced
FIGO (International Federation of Gynecology and Obstetrics)stage IIIc or IV ovarian or peritoneal carcinoma not suitable for
optimal debulking surgery (postsurgical residual disease being zero)
were eligible for this study. Histologic diagnosis and the feasibility of
optimal resection were assessed at baseline by open laparoscopy. The
inclusion criteria were age older than 18 years; histologic diagnosis of
epithelial ovarian or peritoneal carcinoma; hematologic, renal, he-
patic, and cardiac function adequate for platinum- and taxane-based
chemotherapy. The exclusion criteria were Karnofsky Performance
Status lower than 70, pregnancy, history of other malignancies (ex-
cept for nonmelanoma skin cancer and in situ cervical carcinoma) in
the past 5 years. Patients with contraindications for surgery or with
uncontrolled diabetes were also excluded. Physical examination,
computed tomography (CT), and trans-vaginal sonography were
performed on all patients at baseline, every 3 cycles, and upon com-
pletion of NACT. The study was approved by the local ethics com-
mittee, and written informed consent was obtained from all patients.
Treatment
The patients received 6 cycles of carboplatin (AUC5) plus pacli-
taxel (175 mg/m2), administered at 3-week intervals. All the patients
were reassessed for surgery at the end of NACT, the target being to
achieve no postsurgical residual disease (R0). A total anterior hyster-
ectomy plus bilateral salpingo-oophorectomy, radical omentectomy,
and appendectomy were the minimum resections performed in all
optimally operated patients. Apart from that, removal of any meta-
static peritoneal nodule, superficial liver resections, bowel resection,
and splenectomy were performed whenever required. Lymphadenec-
tomy was not routinely performed and was reserved for patients with
no intraperitoneal residual disease and radiologically or clinically
suspect lymph nodes.
FDG-PET Imaging
FDG-PET with CT was carried out at baseline, after 3 cycles, and
at the end of NACT. FDG was produced in the radiopharmacy of the
nuclear medicine unit of our hospital by standardized synthesis tech-
niques. All the tests were performed by using a hybrid PET-CT
scanner (Discovery LS; GE Medical System, Waukesha, WI). FDG-
PET–CT was carried out by standard procedure.23 The patients had
been in fasting condition for at least 6 hours, and the baseline blood
glucose level was 120 mg/dL in all patients enrolled; FDG was
administered intravenously at the dose of 5.3 MBq/kg; imaging ac-
quisition started 60-70 minutes after radiotracer injection. To min-
imize bladder activity, the patients were asked to urinate just before
image acquisition.
PET data were acquired for 4 minutes per bed position, then 35
images were reconstructed after CT data nonuniform attenuation
correction; CT parameters were 120 kV, 60 mA, 0.8 seconds per
tube rotation, 30-mm bed speed per gantry rotation (multislice tech-
nology enabling acquisition of 4–5-mm-thick slices per tube rota-
tion). It was shown that CT does not release a high radiation dose
onto the patient but is still efficient in distinguishing different tissues
with good spatial resolution. CT images were subsequently merged
with PET images to obtain an accurate localization of the FDG-PET
findings. Regions of interest were drawn on the area of abnormal
FDG uptake that corresponded to the tumor in the baseline scan and
likewise after 3 cycles of NACT. The maximum standardized uptake
value (SUVmax) was calculated by using the maximum activity val-
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4 Cliues within each region of interest on the transaxial slices with the
highest radioactivity concentration normalized to the dose injected
and the patient’s body weight according to the following formula:
tissue concentration (MBq/mL) per injected dose (MBq) per body
weight (g). All focal lesions with SUVmax higher than normal in
surrounding tissue uptake (ie, 2) were considered pathologic ac-
cording to revised RECIST (Response Evaluation Criteria In Solid
Tumors) guideline (version 1.1).35
CA-125 Monitoring
Serum CA-125 was determined at baseline and at each chemo-
therapy course. CA-125 was measured at our institutional laboratory
by a commercially available radioimmunoassay, which remained un-
changed throughout the study period.
Assessment of Response
Histopathologic Response. In accordance with the literature on the
esponse to primary chemotherapy in the breast36 and AOC,37,38 we
onsidered a complete pR (pCR) to be the absence of cancer cells in
urgical specimens, and minimal residual disease as a 90% partial
esponse defined by the surgical evaluation with concomitant persis-
ence of only small clusters or individual cancer cells in surgical spec-
mens, as defined by the pathologist. Only patients with pCR and
inimal residual disease were considered as pR, whereas all other
ases were considered as nonresponding (NR).
Metabolic Response. SUVmax obtained after the third cycle of che-
otherapy were compared with baseline SUVmax, which was con-
idered the reference value upon which to obtain the percentage
eduction (SUVmax). Thus, an SUVmax equal to 0% meant no
hange in tumor, SUVmax and SUVmax equal to 100% meant
hat tumor SUVmax during treatment became equal to normal sur-
ounding tissue uptake (values 2). This result was defined as early
omplete metabolic response (e-CMR). If multiple metastatic tu-
ors were present in a patient, then the lesion with the lowest change
n FDG uptake was used for analysis on the rationale that the meta-
tatic tumor with the worst response would determine survival.
In a previous study, the threshold value of the SUVmax, with
ighest positive predictive value (PPV) taken to detect pR was
00%36. A specialist specifically trained in nuclear medicine (P.C. or
.F.) performed the analysis of PET data. Analysis of PETs was
erformed with no knowledge of the CT or other clinical test results.
Biochemical Response. Akin to FDG-PET, CA-125 after 3 cycles
as compared with the baseline value and the percentage reduction
as calculated (CA-125). CA-125 equal to 0% meant no change
n serum CA-125 and CA-125 equal to 100% meant that serum
A-125 was below the normal range (values 35 U/mL). Thus,
early complete biochemical response (e-CBR) corresponded to nor-
malization of the serum marker after 3 cycles.
Statistical Analysis
FDG-PET and CA-125 changes (SUVmax and CA-125) after
3 cycles of NACT were analyzed in correlation with histopathology
specimens by subdividing the patients into pR or NR. We calculated
the accuracy, sensitivity, specificity, and positive predictive value
(PPV) and negative predictive value of a SUVmax and CA-125
nical Ovarian & Other Gynecologic Cancer June 2012threshold of 100% after the third cycle of NACT as successfully
identifying pR. The same cutoff was used to analyze progression-free
survival (PFS) and overall survival (OS). PFS was measured from the
date of NACT initiation to the first documented date of progression,
or death, whichever occurred first. OS was measured from the date of
NACT initiation to the date of death. PFS and OS rates were esti-
mated by means of the Kaplan-Meier method, and comparisons were
made by means of the log-rank test. Multivariate analysis was per-
formed according to the Cox proportional hazards model. All P val-
ues refer to the Wald test of Cox proportional hazards regression.
Ordered categoric variables were coded as continuous variables. All
tests were 2-sided and were performed at a 5% level of significance by
using SPSS for Windows, version 13.0 (SPSS Inc, Chicago, IL).
Results
Fifty consecutive patients with AOC were enrolled from Novem-
ber 2004 to June 2008. The main characteristics of the patients are
listed in Table 1. A baseline histologic diagnosis was obtained by
open laparoscopy in all cases except 4 patients who underwent ex-
plorative laparotomy (2 cases) or transparietal biopsy (2 stage IV
cases). Forty-eight (96%) patients completed 6 cycles of NACT,
whereas 2 patients with stage IV disease stopped the treatment after
5 cycles due to disease progression and poor treatment compliance,
respectively.
Histopathologic Response
Thirteen (26%) of 50 patients did not have surgery because of
clinically progressive disease6 or clinical disease unchanged7 at the
nd of NACT, and were considered NR. Of 37 operated patients, 23
resented pR and 14 did not reach the criteria for pR definition and
ere classified as NR. Hence, of the total 50 patients, the pR rate was
6%, 5 (10%) and 18 (36%) patients reached pCR and minimal
esidual disease, respectively, whereas the NR rate was 54%.
The goal of no macroscopic residual tumor after surgery was
chieved in 26 (52%) patients, including all 23 patients with pR and
additional patients who were NR who were converted to residual
umor equal to zero. Postsurgical residual disease1 and1 cm in
he largest diameter was found in 7 and 4 patients, respectively.
Metabolic and Biochemical Response
Baseline SUVmax was abnormal in all patients (median, 11.5;
range, 3.1-32). After 3 cycles, it significantly decreased (P  .003)
and reached a median value of 3 (range, 2-21). Seventeen (34%)
patients obtained e-CMR. All patients with pR had SUVmax 
50% (median, 100%; range, 51%-100%). By contrast, the 27 pa-
tients classified as NR had SUVmax values widely scattered be-
tween 0% and 100% (median, 33%). The predictive values in terms
of identifying pR and R0 surgery by e-CMR are reported in Tables 2
and 3. For both endpoints, the PPV was equal to 88%.
Baseline CA-125 was abnormal in all but 1 patient (median,
628 U/mL; range, 29-6000 U/mL). After 3 cycles, it decreased
significantly (P  .046) and reached a median value of 90 U/mL
(range, 3-4882 U/mL), and e-CBR was obtained in 19 (38%)
patients. All the patients with pR had CA-125 75% (median,
100%; range, 76%-100%). Again, as with SUVmax, the 27
patients classified as NR had CA-125 values widely scattered
between 0% and 100% (median, 77%). The predictive value in
2e
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Andrea Angelo Martoni et alterms of identifying pR and R0 surgery by e-CBR response is
reported in Tables 2 and 3, and the PPV was 84% and 89%,
respectively.
Simultaneous normalization of both tests (e-CMR and e-CBR) in
the same patient occurred in 11 patients; in these patients, the PPV of
pR or R0 surgery was 100%; in contrast, when normalization oc-
curred in only 1 of the 2 tests, the PPV decreased to 77% and 81%
for pR and postsurgical R0, respectively (Table 4). If lower thresh-
olds are taken to define metabolic response (ie, SUV  55%, ac-
cording to Avril et al33) and biochemical response (ie, CA-125 
75%), the PPV is lowered still further.
PFS and OS. After a median follow-up of 42 months (range,
22-67 months), 41 (82%) patients progressed, and 32 (64%) pa-
Table 1 Baseline Patient Characteristics
Variable Patients(n  50)
Median Age (Range), y 67 (43-79)
Median Karnofsky Performance
Status (Range) 90 (70-100)
Tumor Primary Site (no. of patients
[%])
Ovarian 44 (88%)
Peritoneal 6 (12%)
FIGO Stage
IIIC 29 (58%)
IV 21 (42%)
Histologic Classification (no. of
patients [%])
Serous 34 (68%)
Endometrioid 2 (4%)
Undifferentiated adenocarcinoma 13 (26%)
Clear cell 1 (2%)
Grade (no. of patients [%])
1 1 (2%)
2 2 (4%)
3 43 (86%)
Unknown 4 (8%)
Ascites (>500 mL) (no. of patients
[%])
Yes 43 (86%)
No 7 (14%)
Median Serum CA-125 (Range), U/mL 628 (29-6000)
Serun CA-125 (No. of Patients [%])
CA-125 <35 U/mL 1 (2%)
35 U/ml <CA-125 <500 U/mL 20 (40%)
CA-125 >500 U/mL 29 (58%)
Median SUVmax (Range) 11.5 (3.1-32)
Abbreviation: FIGO International Federation of Gynecology and Obstetrics.tients died. The median PFS was 13.8 months (range, 8.4-19.2months), and the median OS was 28.1 months (range, 17.2-39.1
months). As expected, the pR and postsurgical residual tumor signif-
icantly affected PFS and OS: in particular, patients who were pR and
pathologic NRs had a median PFS of 23.5 and 10.0 months, respec-
tively (P  .001), and a median OS of 52.6 and 19.1 months, re-
spectively (P  .001); the patients with no residual tumor, residual
tumor, and those not operated on had a median PFS of 19.0, 11.8,
and 6.2 months, respectively (P .001), and a median OS of 52.6,
2.8, and 10.0 months, respectively (P  .001).
At monovariate analysis, the patients with e-CMR by FDG-PET had
a statistically higher median PFS and OS than patients who did not reach
CMR (median PFS 27.2 vs. 11.7 months, P  .006; and median OS
52.6 vs. 22.8 months; P .007) (Figure 1). By contrast, patients with
e-CBR had a statistically significant higher median PFS than those who
did not reach normalization of CA-125 levels (21.9 vs. 11.6 months;
P .013), but the difference was not statistically significant as concerns
OS (34.6 vs. 19.9 months;P .073) (Figure 2). Multivariate analysis of
presurgical potential prognostic factors (age, stage, baseline SUVmax,
baseline CA-125,SUV after 3 cycles,CA-125 after 3 cycles) showed
that only CMR significantly affects OS (Table 5).
Discussion
In this exploratory study, we prospectively examined the predic-
tive and prognostic value of FDG-PET changes after 3 cycles of
NACT in 50 patients with AOC, which compared these results with
standard serum CA-125 monitoring. Both early complete metabolic
and biochemical response were able to identify patients who achieved
pR (ie, PPV, 88% and 88%) and R0 surgery (PPV, 84% and 89%)
with a sufficiently high PPV. Thus, in our study, FDG-PET did not
show any substantial superior predictive value over classic monitor-
ing by CA-125. However, if simultaneous normalization of the 2
tests occurred, then the PPV became 100% for both pR and post-
surgical R0. These results suggest that, by using both tests, there is a
high likelihood of identifying patients with chemosensitive tumors
in whom the prolonging of chemotherapy up to 6 cycles would not
be deleterious but actually useful in improving the antitumor effect.
Hitherto, early CA-125 normalization has rarely been used, to our
knowledge, as a way of selecting patients with chemosensitive tumors
and prolonging the duration of NACT. Tate et al39 reported that the
CA-125 regression rate during NACT was able to separate patients into
those with a good prognosis of survival and those with a poor prognosis
after subsequent radical surgery, but their CA-125 regression coefficient
did not correlate with pCR and postsurgical residual tumor.
As concerns the prognostic significance of e-CMR and e-CBR, we
observed that patients with normalization of SUVmax or CA-125 after
3 cycles had a statistically significant higher PFS than patients who did
not achieve complete response. However, when the impact of e-CMR
and e-CBR on OS was analyzed, the difference proved to be statistically
significant only for e-CMR. In addition, of the presurgical factors (age,
stage, baseline SUVmax, baseline CA-125,SUV, andCA-125), only
arly SUVmax normalization proved to be an independent prognostic
actor as concerns both PFS and OS at multivariate analysis.
Avril et al33 carried out the only study to our knowledge on se-
quential FDG-PET monitoring. Their study included 33 patients
with AOC who had undergone 3 cycles of NACT before receiving
IDS and after surgery an additional 3 cycles of chemotherapy. Their
Clinical Ovarian & Other Gynecologic Cancer June 2012 5
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6 Climost significant observation was that patients with metabolic re-
sponse after 1 cycle (defined as SUVmax of 20%), or after 3
ycles, (defined as SUVmax 55%), had a statistically significant
igher OS than patients who were NR. On the contrary, aCA-125
hreshold of 75% or 100% after 3 cycles had no impact on OS.
owever, in their study, they did not analyze the FDG-PET–pR
elationship, which raised doubts as to what usefulness such results
ight have for individual patients if they did not help provide an
rientation toward alternative therapeutic strategies.40
Unlike Avril et al,32 we adopted SUVmax normalization
Table 2 Predictive Value of Optimal Pathologic Response by e-
e-CBR
No. % (95% confidence lim
Sensitivity 16/23 70% (51%-88%)
Specificity 24/27 89% (77%-100%)
PPV 16/19 84% (68%-100%)
NPV 24/31 77% (63%-92%)
Accuracy 40/50 80% (66%-90%)
Abbreviations: CA-125 cancer antigen 125; e-CBR early complete biochemical response (ie
or2); NPV negative predictive value; PPV positive predictive value.
Table 3 Predictive Value of Optimal Surgerya by e-CBR and e-
e-CBR
No. % (95% confidence lim
Sensitivity 16/26 62% (41%-80%)
Specificity 22/24 92% (73%-99%)
PPV 17/19 89% (66%-98%)
NPV 22/31 71% (52%-86%)
Accuracy 38/50 76% (62%-87%)
Abbreviations: CA-125 cancer antigen 125; e-CBR early complete biochemical response (ie
or2); NPV negative predictive value; PPV positive predictive value.
a No macroscopic postsurgical residual tumor.
Table 4 PPV of Early SUV and CA-125 Different
Thresholds and Their Combinations
Total No.
of
Patients
pR (no. of
patients [%])
R0 Surgery (no.
of patients [%])
e-CMR (SUV 100%) 17 15 (88%) 15 (88%)
e-CBR (CA-125 100%) 19 16 (84%) 17 (89%)
e-CMR and e-CBR 11 11 (100%) 11 (100%)
e-CMR or e-CBR 26 20 (77%) 21 (81%)
e-CMT (SUV 55%a) 30 22 (73%) 22 (73%)
e-CBR (CA-125 75%a) 38 23 (61%) 24 (63%)
Abbreviations: CA-125  cancer antigen 125; CBR  complete biochemical response; CMR 
omplete metabolic response; PPV positive predicative value; pR optimal pathologic response;
0 surgery no macroscopic postsurgical residual tumor; SUV standardized uptake value.
a According to Ref.33.(SUVmax  100%), instead of lower thresholds, on the basis of t
nical Ovarian & Other Gynecologic Cancer June 2012our previous observations.36 Even with this difference in the meta-
olic response definition, our results substantially confirm the obser-
ation of Avril et al,32 that metabolic response by FDG-PET after 3
cycles of NACT is an independent prognostic factor. Likewise, we
confirm that early CA-125 normalization has no independent prog-
nostic value, in agreement with Avril et al32 and other
researchers.18,23,41
What could the position of FDG-PET be in the treatment of
patients with AOC? Analysis of the results of our study suggests that,
when NACT is chosen as the primary treatment, FDG-PET has a
potential role in the early identification of those patients who opti-
mally respond to NACT and who will achieve optimal surgery after
completion of NACT. It means that these patients, who form 34% of
our entire series (17/50), might continue to receive chemotherapy for
up to 6 cycles, even if they are already candidates for IDS after 3
cycles. By contrast, a partial metabolic response (SUVmax 100)
after 3 cycles could guide treatment toward immediate IDS and
postpone further chemotherapy cycles. In this case, an alternative
chemotherapy regimen might also be considered. This assertion is
quite speculative, however, and should be supported by a specifically
oriented study.
Analysis of our study results also suggests that early metabolic
response by FDG-PET could be an independent prognostic factor in
patients with AOC. The same observation has been made in other
clinical settings, including lymphomas42 and esophageal,43 head and
eck,44 rectal,45 and cervical cancers.46 The cost of two PET scans
baseline and after 3 cycles of NACT) that are needed in the hypo-
and CMR
e-CMR
No. % (95% confidence limits)
15/23 65% (46%-85%)
25/27 93% (83%-100%)
15/17 88% (73%-100%)
25/33 76% (61%-90%)
40/50 80% (66%-90%)
125 100%; or35 UI/mL); e-CMR early complete metabolic response (ie,SUVmax 100%;
e-CMR
No. % (95% confidence limits)
22/26 85% (65%-96%)
21/24 87.5% (68%-97%)
15/17 88% (64%-99%)
22/33 67% (48%-82%)
37/50 74% (60%-85%)
125 100%; or35 UI/mL); e-CMR early complete metabolic response (ie,SUVmax 100%;CBR
its)CMR
its)
,CA-hetical proposed strategy is certainly not comparable to the cheaper
Andrea Angelo Martoni et alstandard monitoring of CA 125. However, our study shows that,
while not offering substantial advantages in predicting pathologic
response, PET is clearly superione to CA 125 for prognostic infor-
mation provided. This information could become important in the
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8 Clisubsequent treatment options, needs to be confirmed by a larger trial.
Another possible criticism is that we assume, but do not prove, that,
before SUVmax normalization after 3 cycles, a further 3 cycles are
necessary to achieve an pR and R0 surgery.
Another observation could be the use of carboplatin dose AUC5
and not AUC6. We don’t know any study that demonstrated supe-
riority of the higher dose of the platinum derivative and recently the
combination of paclitaxel 175 mg/m2 paclitaxel i.v.over 3 h, fol-
owed by carboplatin as an i.v. infusion over 30-60 min at a dose
djusted to produce an AUC of 5-6 mg_ml/min and to repeat this
very 3 weeks for six cycles was confirmed to be the first-line chemo-
herapy for ovarian cancer. by Fourth International Ovarian Cancer
onsensus Conference, the Gynecologic Cancer InterGroup.47
In conclusion, this study indicates that patients with e-CMR after
the third cycle of NACT have a high likelihood of obtaining an pR
and achieving R0 surgery after a total of 6 cycles. In this subset of
patients, dual-time FDG-PET could lead to a therapeutic option
other than the one recommended today and, at the same time, may
provide important information on long-term patient outcome more
accurately than is provided by CA-123 monitoring. Given the ex-
ploratory character of this study and its small sample size, confirma-
tory investigations are required.
Clinical Practice Points
● Only one small study investigated the role of FDG-PET/TC dur-
ing NACT for advanced ovarian cancer (AOC) prior to surgery.
The metabolic response after 1 or 3 cycles of NACT was associated
with better OS than patients who did not respond. This informa-
tion, however, had no impact on decision making for individual
patients because all had undergone surgery after the 3rd cycle of
NACT.
● In our study including 50 AOC patients, the duration of NACT
was predetermined for 6 cycles before definitive surgery and the
metabolic response with FDG-PET/TC was evaluated after 3 cy-
cles. The complete metabolic response occurred in 17 patients and
in 15 of them (88%), an optimal pathological response and a R0
surgery has been reached. If changes in CA 125 serum levels were
also considered, all patients showing simultaneously complete
metabolic and biochemical response after 3 cycles, obtained an
optimal pathological response and an optimal surgery. In addition
Table 5 Multivariate Analysis of Presurgical Prognostic Factor
Covariates
P
P HR
Age .359 0.700
Stage .368 1.345
Baseline SUVmax .384 0.729
Baseline CA-125 .833 1.082
SUV After 3 Cycles (100% vs. <100%) .016 0.378
CA-125 After 3 Cycles 100% vs. <100%) .221 0.611
Abbreviations: CA-125 cancer antigen 125; HR hazard ratio; OS overall survival; PFS prothe complete metabolic response, but not the biochemical one,
nical Ovarian & Other Gynecologic Cancer June 2012identifies patients with a very good prognosis (median OS 52.6
months).
● A FDG-PET/TC scan might be added in the workup of AOC
patients undergoing NACT and repeated after 3 cycles. The com-
plete metabolic response could help to identify patients with
highly chemosensitive tumours in which it would be justified to
extend the duration of NACT before performing the surgery.
Conversely, the intervention should be provided immediately in
the other patients less responsive. Given the exploratory character
of our study confirmatory investigations are required.
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